Clovis Oncology
Clovis Oncology is a small pharmaceutical company which mainly markets products for treatment in oncology.[1] Depomed was founded in 2009 and is headquartered in Dover, Colorado.[2] The company is a publicly traded company on NASDAQ under the symbol "CLVS" [3] and is in the NASDAQ Biotechnology Index[4] with several products in its product pipeline.[5]
Pipeline
Its products include:
Rociletinib
It is developing rociletinib,[6] which is in development as a treatment for non-small cell lung cancer.[1][7][8][9]
A phase III trial has completed and in April 2016 an FDA committee will consider recommending it for marketing approval.[10] If approved it would compete with AstraZeneca's Tagrisso (osimertinib).[10]
Rucaparib
Rucaparib is a PARP inhibitor in Phase II and III clinical trials for advanced ovarian cancer.[11]
Lucitanib
Lucitanib is a VEGFR inhibitor.[12]
References
- ^ a b "Clovis Oncology: A Winning Or Losing Lottery Ticket?". Forbes. 2015-11-16. Retrieved 2016-01-04.
- ^ "CLVS Profile". finance.yahoo.com.
- ^ "Clovis Oncology Inc". www.marketwatch.com. Retrieved 4 January 2016.
- ^ "Overview NBI". nasdaq.com. Retrieved 4 January 2016.
- ^ "Clovis Oncology - Products & Companion Diagnostics". Clovisoncology.com. 9 March 2015. Archived from the original on March 9, 2015. Retrieved 4 January 2016.
{{cite web}}: Unknown parameter|deadurl=ignored (|url-status=suggested) (help) - ^ Williams, Sean (23 December 2015). "A Festivus for the Invest in Us -- It's Time for the Airing of Grievances". Fox Business. Retrieved 4 January 2016.
- ^ Wallace, Alicia. "Clovis Oncology stock bludgeoned after delay in cancer drug approval". www.denverpost.com. Retrieved 4 January 2016.
- ^ "hClovis Oncology Announces Regulatory Update for Rociletinib NDA Filing". www.reuters.com. Retrieved 4 January 2016.
- ^ "FDA Requests Additional Data for Rociletinib in EGFR T790M-Mutant NSCLC". OncLive. 2015-11-16. Retrieved 2016-01-04.
- ^ a b Investors doubt efficacy of Clovis lung cancer med rociletinib, shares off 11%. April 2016
- ^ Rucaparib at Clovis
- ^ Lucitanib at Clovis